StockMarketWire.com - ANGLE says highly promising results from first phase work with its Parsortix system on a liquid biopsy for breast cancer by the University of Southern California Norris Comprehensive Cancer Center will be presented today.

Dr Julie E. Lang, associate professor of surgery, specialising in breast cancer and notably in molecular profiling of circulating tumour cells (CTCs) in breast cancer, will present results from USC's work with ANGLE's Parsortix system at the World CDx Conference in Boston. USC has compared the RNA molecular results of a liquid biopsy using the Parsortix system (simple blood test) with those from the biopsy of metastatic sites (the secondary cancer locations) in metastatic breast cancer patients. The main findings from the first four patients are as follows: 1) In all of the patients analysed, the Parsortix system provided highly enriched CTCs suitable for rare cell amplification and RNA Seq analysis to detect relevant biomarkers and potentially discover novel biomarkers in breast cancer. 2) The CTCs for the Parsortix liquid biopsy had similar patterns of gene expression to the traditional biopsy of cancer cells from metastatic sites. 3) There was some degree of heterogeneity in the CTCs, which suggests they may provide additional clinical information beyond that found at a single metastatic site and may be representative of multiple metastatic sites.


At 8:14am: [LON:AGL] Angle PLC share price was +2.5p at 82p



Story provided by StockMarketWire.com